Skip to main content
. Author manuscript; available in PMC: 2020 Oct 5.
Published in final edited form as: Breast Cancer Res Treat. 2020 Jun 5;182(3):613–622. doi: 10.1007/s10549-020-05709-z

Table 1.

Patient Characteristics (N=30)

Characteristic N (%)

Age (median) 54.5 (29-70)

Age Group:
<40 4 (13)
40-49 7 (23)
50-59 9 (30)
≥ 60 10 (16)

Race:
White 29 (97)
Other 1 (3)

Menopausal Status:
Pre-menopausal 10 (33)
Post-menopausal 20 (67)

ER/PR Status:
ER or PR Positive 20 (67)
ER and PR Negative 10 (33)

Previous Breast Surgery:
Breast Conserving 7 (23)
Mastectomy 23 (77)

Nodal Status:
Node Positive (1-3+ nodes) 9 (30)
Node Positive (4-9+ nodes) 1 (3)
Node Positive (10+ nodes) 3 (10)
Node Negative 17 (57)

Nottingham Tumor Grade:
Well /Intermediate 7 (23)
Poor 23 (77)

Histology:
InvasiveDuctal 26 (87)
InvasiveLobular 4 (13)

Size (cm)
<1 1 (3)
1-2 11 (37)
2-5 13 (43)
> 5 5 (17)

Side of Tumor
Left 15 (50)
Right 15 (50)

Performance Score
0 21 (70)
1 9 (30)

Smoking Status
Never 20 (67)
Current 4 (13)
Former 6 (20)

History of Diseases:
Diabetes 2 (7)
Hypertension 9 (30)
Other 9 (30)
None 20 (67)

Any Prior Cancer
Yes 1 (3)
No 29 (97)

Planned Hormone Therapy
Tamoxifen 6 (20)
Aromatase Inhibitor 10 (33)
None 14 (47)

Planned Radiation Therapy
Yes 14 (47)
No 16 (53)